Journal
CLINICAL INFECTIOUS DISEASES
Volume 53, Issue 2, Pages 158-163Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir340
Keywords
-
Categories
Funding
- Sharp Healthcare Foundation
- Cubist Pharmaceuticals
- Astellas Pharmaceuticals
- Cubist
- Pfizer Pharmaceuticals
- Astellas
- Ortho-McNeil Pharmaceuticals
Ask authors/readers for more resources
We used daptomycin plus antistaphylococcal beta-lactams (ASBL) to clear refractory MRSA bacteremia. In vitro studies showed enhanced daptomycin bactericidal activity, increased membrane daptomycin binding, and decrease in positive surface charge induced by ASBLs against daptomycin nonsusceptible MRSA. Addition of ASBLs to daptomycin may be of benefit in refractory MRSA bacteremia. (Although the official designation is daptomycin nonsusceptiblity, we will use the term daptomycin-resistance in this paper for facility of presentation.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available